BioLine Rx (FRA:YP2) Other Current Liabilities: €1.50 Mil (As of Mar. 2026)


FRA:YP2 BioLine Rx Ltd FRA:YP2
21 GF Score
Price €2.52
! 5 Warning Signs
View Full Analysis

What is BioLine Rx Other Current Liabilities?

BioLine Rx FRA:YP2 21 Other Current Liabilities is €1.50 Mil as of Mar. 2026. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review.

BioLine Rx's other current liabilities for the quarter that ended in Mar. 2026 was €1.50 Mil.

BioLine Rx's quarterly other current liabilities declined from Sep. 2025 (€2.75 Mil) to Dec. 2025 (€2.12 Mil) and declined from Dec. 2025 (€2.12 Mil) to Mar. 2026 (€1.50 Mil).

BioLine Rx's annual other current liabilities declined from Dec. 2023 (€11.33 Mil) to Dec. 2024 (€2.03 Mil) but then increased from Dec. 2024 (€2.03 Mil) to Dec. 2025 (€2.12 Mil).

BioLine Rx Other Current Liabilities Related Terms

BioLine Rx Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for BioLine Rx's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx Other Current Liabilities Chart

BioLine Rx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.36 11.33 2.03 2.12

BioLine Rx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.28 3.78 2.75 2.12 1.50
FRA:YP2
21GF Score
BioLine Rx Ltd FRA:YP2
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €1.50 Mil mean?
BioLine Rx (FRA:YP2) has a Other Current Liabilities of €1.50 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on BioLine Rx.
Is BioLine Rx's Other Current Liabilities too high?
BioLine Rx's current Other Current Liabilities is €1.50 Mil. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Other Current Liabilities compare to VRTX and REGN?
BioLine Rx's Other Current Liabilities of €1.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on BioLine Rx. BioLine Rx's current Other Current Liabilities is €1.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (FRA:YP2) has a current Other Current Liabilities of €1.50 Mil. The current Other Current Liabilities is €1.50 Mil. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current Other Current Liabilities is €1.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Other Exchanges BLRX:USABLRX:Israel
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score

Get the complete analysis for FRA:YP2

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price